Lakewood-Amedex Biotherapeutics Inc. (LABT) Form 10-Q — Aug 13, 2026
Lakewood-Amedex Biotherapeutics (LABT) reported a Q2 2026 net loss of $3.77 million ($2.75 per share) and a first-half net loss of $4.70 million ($5.01 per share), versus $0.66 million and $1.20 million a year earlier. The clinical-stage biotech generated no revenue and is preparing a Phase 2a dose-comparison study of its lead candidate Nu-3 (Bisphosphocin gel) in infected diabetic foot ulcers.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 4960009
- Cash Position
- 2584774
- Shares Outstanding
- 2369688
- Funding runway
- sufficient liquidity into Q1 2027
- Net loss period
- six months ended June 30, 2026
- Working capital
- approximately $4.2 million
- Ga expense q2 2026
- 3285481
- Ga expense yoy pct
- 571%
- Rd expense q2 2026
- 503020
- Rd expense yoy pct
- 242%
- Reverse split 2025
- 1:5.92 effective September 29, 2025
- Reverse split 2026
- 1:10 effective June 19, 2026
- Stockholders equity
- 4331083
- Series c net proceeds
- 6802095
- Series c dividend rate
- 12% per annum, cumulative
- Series c gross proceeds
- 7500000
- Series c conversion terms
- lesser of $10.00 or 80% of lowest closing price during prior 5 trading days, $1.00 floor, 4.99% ownership cap
- Series c shares outstanding
- 497157
- Series c original issue discount
- 20%
- Shares issued to sec counsel value
- 75000
- Investments certificates of deposit
- 2000000
- Placement agent advisory shares value
- 2359080
- Convertible notes converted at listing
- 1500000
Price after filing
1 day: -2.6%7 days: -6.0%30 days: -4.7%
Close on the filing date to close N calendar days later (from $2.33). Historical, not a forecast.
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.